Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors

1 Apr 2025

Abstract excerpt

Many patients with cancer do not benefit from currently approved immune checkpoint inhibitors (ICIs), suggesting that additional immunomodulation of the immunosuppressive tumor microenvironment (TME) is required. MTL-CCAAT enhancer-binding protein alpha (CEBPA) specifically upregulates the expression of the master myeloid transcription factor, CEBPA, relieving myeloid-driven immunosuppression. Here, we report the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Cancer Research and Treatments
Share to CAR-T cell therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40168999
DOI: 10.1016/j.xcrm.2025.102041

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsPMID 40168999Read ↗

Insights into the Mechanisms of Immune‐Checkpoint Inhibitors Gained from Spatiotemporal Dynamics of the Tumor MicroenvironmentSemantic proximity Read ↗

Tumor microenvironment changes after treatment with avelumab and immune- stimulating agent combinations in patients with advanced solid tumorsSemantic proximity Read ↗

Therapeutic Blockade of Type 2 Cytokines and PD1 Unleashes Anti-Tumor Immunity Through Coordinated Reprogramming of Innate and Adaptive Immune SurveillanceSemantic proximity Read ↗

Biomarker study of pembrolizumab in patients with advanced rare cancers.Semantic proximity Read ↗

Advancements and Challenges in Personalized Therapy for BRAF-Mutant Melanoma: A Comprehensive ReviewSemantic proximity Read ↗

Pazopanib induces dramatic but transient contraction of myeloid suppression compartment in favor of adaptive immunitySemantic proximity Read ↗

Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapySemantic proximity Read ↗

Systematic identification and targeting of master regulator checkpoints (MRC) governing tumor microenvironment-mediated immune evasionSemantic proximity Read ↗

Tuning the Tumor Myeloid Microenvironment to Fight CancerSemantic proximity Read ↗

Prediction of pan-solid tumor pembrolizumab benefit by integrating tumor mutation and gene expression profilingSemantic proximity Read ↗

Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the uglySemantic proximity Read ↗

Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.